Fig 3.

Bioavailability and activity of MMV1557817 in murine models. (A) Upper panel: plasma concentration versus time profiles for MMV1557817 following oral dosing (50 mg/kg) to non-infected male Swiss outbred mice. Concentrations are the total measured concentrations and calculated unbound concentrations (obtained by multiplying the total concentration by the fraction unbound in mouse plasma). The unbound P. falciparum EC₅₀ value for MMV1557817 is shown for comparison. Lower panel: plasma exposure parameters in Swiss outbred mice following oral administration. (B) Peter’s test performed on Balb/c mice infected with P. berghei ANKA parasites and treated with 50 mg/kg MMV1557817 or 30 mg/kg artesunate on days 0, 1, 2, and 3 post-infection and parasite clearance determined on day 4. MMV1557817 was found to clear 95.4% of infection. Significance was determined using an unpaired t-test; n ≥ 4.